Expert Opinion on Drug Metabolism & Toxicology

Papers
(The H4-Index of Expert Opinion on Drug Metabolism & Toxicology is 19. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)
ArticleCitations
Probing the mechanism of reduced in vivo potency of insulin detemir118
A three-arm clinical study to compare pharmacokinetic and pharmacodynamic similarity of the denosumab biosimilar LY06006 with reference denosumab in healthy male subjects111
Unraveling Ritlecitinib: an in-depth analysis of JAK3 inhibitor for the treatment of alopecia areata69
An update on pharmacogenetic factors influencing the metabolism and toxicity of artemisinin-based combination therapy in the treatment of malaria60
The Central Role of Cytochrome P450 Reductase (CPR) in Hyperoxic Lung Injury58
Hormones, microbes, and PrEP drugs in the female genital tract51
Pharmacokinetics of S1P receptor modulators in the treatment of ulcerative colitis48
Comorbidities and the right dose: antipsychotics32
The impact of genomic variants on patient response to inhaled bronchodilators: a comprehensive update32
Azole antifungals and inter-individual differences in drug metabolism: the role of pharmacogenomics and precision medicine30
Pharmacotherapy in kidney disease: what it takes to move from general guidance to specific recommendations to stratified subgroups of patients - the tale of autosomal dominant polycystic kidney diseas27
Guidance for interactions between antiseizure medications26
A real-world data analysis of topotecan in the FDA Adverse Event Reporting System (FAERS) database25
Immune-mediated liver injury caused by immune checkpoint inhibitors exhibits distinct clinical features that differ from autoimmune hepatitis24
Current status and future perspectives on the use of therapeutic drug monitoring of thiopurine metabolites in patients with inflammatory bowel disease23
In NAMs we trust – an innovative paradigm-shift in risk-based chemicals management for globally harmonized protection goals23
Pharmacokinetic and toxicodynamic concepts in idiosyncratic, drug-induced liver injury22
Correction21
Bioactivity descriptors for in vivo toxicity prediction: now and the future21
A comprehensive review of the efficacy and safety of ertugliflozin19
Pharmacokinetic, toxicological, and clinical considerations for the treatment of type 2 diabetes in patients with liver disease: a comprehensive update19
0.0832359790802